Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer | MicrobiomeTrials← Back to trialsNCT07645651
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-07-01Est. Completion: 2027-07-14
Enrollment target: 15 participants Locations- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Other microbiome trials you might be interested in
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) exhibits significant heterogeneity, making the optimal choice of chemotherapy ch…
Clichy, FranceEst. completion Apr 2029
Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC), representing 85-95% of pancreatic cancers, is a highly lethal malignancy with a…
Shenyang, ChinaEst. completion Dec 1, 2026